Skip to main content

Table 2 HNSCC, postoperative radio- radiochemotherapy by PSMD1-score

From: Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients

PSMD1-score 1 (n=26) 2 (n=27) 3 (n=39)
Age (years) mean 63.4 60.8 60.2
Q1/Q2/Q3 58.5/64/70.2 52/60/70 51/61/68
Male (%) 88.4 81.4 73.6
Weight (kg) mean 64.9 68.8 67.7
Q1/Q2/Q3 57.8/64.5/73 56.8/68.8/77.5 57.8/68.7/77.6
Smoker (n) 7/26 17/26 17/39
Karnofski >= 70% (n) 19/19 19/20 30/30
Hemoglobin level (mg/dL) mean 12.7 12.7 12.0
Q1/Q2/Q3 12.0/12.6/13.6 11.1/13.1/14 11.2/11.9/12.9
Unknown primary   1 (3.7)  
Oral cavity n (%) 7 (26.9) 8 (29.6) 9 (23.0)
Oropharynx n (%) 9 (34.6) 10 (37.0) 16 ( 41.0)
Hypopharynx n (%) 5 (19.2) 2 (7.4) 8 (20.5)
Larynx n (%) 5 (19.2) 6 (22.2) 6 (15.3)
cT0 n (%)   1 (3.8) 3 (7.6)
cT1 n (%) 7 (26.9) 2 (7.6) 7 (17.9)
cT2 n (%) 8 (30.7) 8 (30.7) 11 (28.2)
cT3 n (%) 6 (23.0) 6 (23.0) 11 (28.2)
cT4 n (%) 5 (19.2) 9 (34.6) 7 (17.9)
cN0 n (%) 2 (7.6) 6 (22.2) 5 (12.8)
cN1 n (%) 5 (19.2) 4 (14.8) 14 (35.8)
cN2 n (%) 18 (69.2) 14 (51.8) 19 (48.6)
cN3 n (%) 1 (3.8) 3 (11.1) 1 (2.5)
G1 n (%)   1 (3.7) 1 (2.5)
G2 n (%) 12 (46.1) 15 (55.5) 21 (53.8)
G3 n (%) 14 (53.8) 11 (40.7) 17 (43.5)
EpoR (C20+) (%) 17 (65.3) 24 (88.8) 26 (66.6)
RT (Gy) mean 62.9 63.9 62.2
Q1/Q2/Q3 60/64/64 63/64/66 60/63/64
RT (days) 46.9 46.3 45.7
Q1/Q2/Q3 43/45/48 44/45/50 43.7/44.5/47.5
Treated in study A1/C3/D4 (n) 3/22/1 6/18/3 4/31/4
Local control (months) median nr nr nr
Survival (months) median; 95% CI 48.2; 12.4-92.6 29.3; 13–74.1 42.8; 20.7-66.2